Publication type
Report
Author
Publication date
October 8, 2025
Summary:
Overview:
Evidence-based recommendations on garadacimab (Andembry) for preventing recurrent attacks of hereditary angioedema in people 12 years and over.
Last reviewed: 08 October 2025
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
Subjects
Link
https://www.nice.org.uk/guidance/ta1101
Notes
References: Pennington, B.M., Alava, M.H., and Strong, M. (2025) 'Unpaid caring and heath-related quality of life: longitudinal analysis of Understanding Society (the UK Household Longitudinal Survey)', Value in Health, 28(1):138-147. https://doi.org/10.1016/j.jval.2024.08.004
#589074